- Home
- MODD vs MURA Comparison
MODD vs MURA Comparison
Compare MODD & MURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MODD
- MURA
- Stock Information
- Founded
- MODD 1998
- MURA 2013
- Country
- MODD United States
- MURA Ireland
- Employees
- MODD N/A
- MURA N/A
- Industry
- MODD Industrial Specialties
- MURA
- Sector
- MODD Health Care
- MURA
- Exchange
- MODD Nasdaq
- MURA Nasdaq
- Market Cap
- MODD 33.0M
- MURA 36.0M
- IPO Year
- MODD N/A
- MURA N/A
- Fundamental
- Price
- MODD $0.42
- MURA $2.02
- Analyst Decision
- MODD
- MURA Buy
- Analyst Count
- MODD 0
- MURA 2
- Target Price
- MODD N/A
- MURA $6.00
- AVG Volume (30 Days)
- MODD 1.7M
- MURA 182.1K
- Earning Date
- MODD 11-14-2025
- MURA 11-06-2025
- Dividend Yield
- MODD N/A
- MURA N/A
- EPS Growth
- MODD N/A
- MURA N/A
- EPS
- MODD N/A
- MURA N/A
- Revenue
- MODD N/A
- MURA N/A
- Revenue This Year
- MODD N/A
- MURA N/A
- Revenue Next Year
- MODD N/A
- MURA N/A
- P/E Ratio
- MODD N/A
- MURA N/A
- Revenue Growth
- MODD N/A
- MURA N/A
- 52 Week Low
- MODD $0.28
- MURA $0.95
- 52 Week High
- MODD $1.82
- MURA $4.74
- Technical
- Relative Strength Index (RSI)
- MODD 32.14
- MURA 34.33
- Support Level
- MODD $0.28
- MURA $2.06
- Resistance Level
- MODD $0.57
- MURA $2.10
- Average True Range (ATR)
- MODD 0.05
- MURA 0.02
- MACD
- MODD -0.01
- MURA -0.00
- Stochastic Oscillator
- MODD 46.00
- MURA 6.25
About MODD Modular Medical Inc.
Modular Medical Inc is a development stage medical device company which focuses on the design, development, and commercialization of insulin pumps using modernized technology to increase pump adoption in the diabetes marketplace. The company's products seek to serve both the type 1 and the rapidly growing, especially in terms of device adoption, type 2 diabetes markets.
About MURA Mural Oncology plc
Mural Oncology PLC is a clinical-stage oncology company whose entire business is focused on discovering and developing immunotherapies that may meaningfully improve the lives of patients with cancer. By leveraging its core competencies in immune cell modulation and protein engineering, It has developed a portfolio of novel, investigational cytokine therapies designed to address areas of unmet need for patients with a variety of cancers. Its product candidate, Nemvaleukin is an investigational, engineered interleukin-2 cytokine designed to capture and expand the therapeutic benefits of high-dose recombinant human IL-2 while mitigating its hallmark toxicities.